SCHEMBL7794562

SCHEMBL7794562

COCCCNc1ccc(C)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.61
SMN1; SMN2 Q16637 2/20 0.48
LMNA P02545 1/20 0.48
HTT P42858 1/20 0.48
ALDH1A1 P00352 2/20 0.46
NPC1 O15118 1/20 0.46
ALOX12 P18054 1/20 0.46
RAB9A P51151 1/20 0.46
PTPN1 P18031 1/20 0.46
KDM4E B2RXH2 2/20 0.45
GAA P10253 1/20 0.45
KCNH3 Q9ULD8 1/20 0.45
POLB P06746 1/20 0.45
DRD2 P14416 2/20 0.44
DRD4 P21917 2/20 0.44
DRD3 P35462 2/20 0.44
PPARG P37231 1/20 0.44
ABCB11 O95342 1/20 0.43
CYP3A4 P08684 1/20 0.43
ADRA2B P18089 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21256829 0.94 MAPT (0.59) MAPTSMN1; SMN2LMNAHTTALDH1A1
SCHEMBL8264100 0.88 MAPT (0.67) MAPTSMN1; SMN2LMNAHTTALDH1A1
SCHEMBL11518048 0.83 MAPT (0.80) MAPTHTTALDH1A1NPC1RAB9A
SCHEMBL31010382 0.82 ALDH1A1 (0.46) MAPTALDH1A1ALOX12PTPN1KDM4E
SCHEMBL11312557 0.82 KCNH3 (0.44) MAPTALDH1A1GAAKCNH3PPARG
SCHEMBL6646246 0.82 ALDH1A1 (0.64) MAPTSMN1; SMN2LMNAALDH1A1KDM4E
SCHEMBL11794172 0.81 SCN5A (0.51) MAPTLMNAALDH1A1RAB9AKDM4E
SCHEMBL22680864 0.79 CA1 (0.44) MAPTSMN1; SMN2LMNAHTTALDH1A1
SCHEMBL27589346 0.79 SCN5A (0.43) MAPTLMNAALDH1A1RAB9AKDM4E
SCHEMBL13450943 0.78 F2 (0.50) MAPTSMN1; SMN2LMNAHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230321033-A1 THIOPHEN COMPOUNDS FOR USE IN THE TREATMENT OF RENAL FIBROSIS ENYO PHARMA (FR) 2023-10-12 US disclosed
US-11767316-B2 Non-fused thiophene derivatives and their uses ENYO PHARMA (FR) 2023-09-26 US disclosed
US-11767316-B2 Non-fused thiophene derivatives and their uses ENYO PHARMA (FR) 2023-09-26 US disclosed
US-20210040059-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES Institut National de la Santé et de la Recherche Médicale (FR) 2021-02-11 US disclosed
WO-2019154956-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 WO disclosed
EP-1150963-A1 SUBSTITUTED 4-AMINO-2-ARYLTETRAHYDROQUINAZOLINES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Aventis Pharma Deutschland GmbH (DE) 2001-11-07 EP disclosed
WO-2000046214-A1 SUBSTITUTED 4-AMINO-2-ARYLTETRAHYDROQUINAZOLINES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210040059-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES FTH1, SLC40A1, FECH MAPT 2844/4885SMN1; SMN2 3896/4885LMNA 4792/4885
US-11767316-B2 Non-fused thiophene derivatives and their uses FTH1, SLC40A1, FECH MAPT 2844/4885SMN1; SMN2 3896/4885LMNA 4792/4885
US-20230321033-A1 THIOPHEN COMPOUNDS FOR USE IN THE TREATMENT OF RENAL FIBROSIS TST, TPMT, MMP1 MAPT 4017/4885SMN1; SMN2 4716/4885LMNA 4369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.